medigraphic.com
SPANISH

Revista Mexicana de Mastología

ISSN 1870-2821 (Print)
Organo Oficial de la Asociación Mexicana de Mastología
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2019, Number 2-3

<< Back Next >>

Rev Mex Mastol 2019; 9 (2-3)

Diagnostic Concordance among BIRADS report by interventional radiology and histopathological diagnosis in patients with breast biopsy

Ponce-Partida RK, Murillo-Ortiz BO, Rivera-Villanueva TM, Murguía-Pérez M
Full text How to cite this article

Language: Spanish
References: 19
Page: 44-52
PDF size: 310.08 Kb.


Key words:

Concordance, BIRADS, histopathology, breast cancer.

ABSTRACT

Background: There are several modalities for the study of breast cancer, including mammography, ultrasound and magnetic resonance; others are image-guided percutaneous biopsy, cutting needle biopsy, marking and surgical biopsies (incisional and excisional). In the patients included in the study, the definitive diagnosis of breast cancer was made by biopsy, this was the most common surgical procedure and considered the gold standard for the diagnosis of palpable or radiological abnormalities. Objectives: To analyze the concordance of the Breast Imaging Reporting and Data System (BIRADS) report by interventional radiology and the histopathological diagnosis in patients with a breast biopsy. Determine the most frequent imaging and BIRADS presentation. Know the frequency of the histological type. To know the frequency of the types of biopsy used, in patients submitted to a breast biopsy in the Unidad Médica de Alta Especialidad (UMAE) No. 1 León, Guanajuato. Methodology: The cases from January to December 2017 were analyzed. It was performed in the Radiology and Image and Pathology Service of the UMAE No. 1 Bajío clinic. The variables were analyzed: age, histopathological report, and radiological evaluation of the breast. Concordance analysis was used to calculate sensitivity and specificity, positive and negative predictive value, and kappa value. Results: We included 94 patients with a mean age of 51.30 ± 10.86 years, who underwent a mammography study and had a radiological diagnosis that required an image biopsy with suspicion of malignancy. The frequency of the categories was as follows: BIRADS 3: 17 (18.18%) (7 complex cysts, 10 fibroadenomas), BIRADS 4A: 58 (61.7%), BIRADS 4B: 12 (12.7%), BIRADS 4C: 5 (5.3%), BIRADS 5: 2 (2.12%), the biopsies performed were trucut 57 (60.6%), breast fine needle aspiration (BFNA) 12 (12.7%) and ultrasound marking 25 (26.6%). The histopathological diagnosis of mammary carcinoma was confirmed in 20 (21%) biopsies, 90% ductal and 10% infiltrating lobulillar. When analyzing the concordance between the cases with BIRADS 4A, B, C, BIRADS 5 with the histopathological diagnosis, a kappa of 0.75 was obtained, which corresponds to a considerable concordance. Conclusions: The biopsy performed under the range of procedures done by interventional radiology of breast has a high concordance of 0.75. Its advantages are many, little ionizing radiation, widely available equipment, access to all mammary areas, visualization of the biopsy needle in real time, multidirectional sampling, low rate of complications, allows better planning of surgery, low cost, greater patient comfort and speed of execution, a strategy that benefits in time and costs the timely diagnosis of breast cancer.


REFERENCES

  1. Breast Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Disponible en http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp.

  2. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer de mama. Séptima revisión. Colima 2017. Gaceta Mexicana de Oncología. 2017; 16 (Supl. 1): 1-78.

  3. International Agency for Research on Cancer, Global Cancer Observatory. Disponible en: http://gco.iarc.fr/.

  4. Jansen SA, Shimauchi A, Zak L, Fan X, Wood AM, Karczmar GS et al. Kinetic curves of malignant lesions are not consistent across MRI systems: need for improved standardization of breast dynamic contrast-enhanced MRI acquisition. AJR. 2009; 193: 832-839.

  5. Agrawal G, Su MY, Nalcioglu O, Feig SA, Chen JH. Significance of breast lesion descriptors in the ACR BI-RADS lexicon. Cancer. 2009; 115: 1363-1380.

  6. Ortiz de Iturbide MC, Carrasco-Ortiz A. Actualidades en la detección oportuna de cáncer mamario: mastografía y ultrasonido. Acta Médica Grupo Angeles. 2016; 14: S1-S16.

  7. Abramson RG, Arlinghaus LR, Weis JA, Li X, Dula AN, Chekmenev EY et al. Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. Breast Cancer. 2012; 4: 139-154.

  8. D’Orsi CJ, Sickles EA, Mendelson EB, Morris EA. ACR BI-RADS atlas, breast imaging reporting and data system. Reston, VA: American College of Radiology; 2013.

  9. Gilbert FJ, Tucker L, Gillan MG, Willsher P, Cooke J, Duncan KA et al. The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme--a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. Health Technol Assess. 2015; 19 (4): i-xxv, 1-136.

  10. Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010; 7: 18-27.

  11. Stravos AT, Rapp CL, Parker SH. Ecografía de mama. 2a edición. Madrid, España: 2012. pp. 136-139.

  12. NOM-041-SSA2-2011, Para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer de mama.

  13. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007; 356: 227-236.

  14. Liberman L, Feng TL, Dershaw DD, Morris EA, Abramson AF. US-guided core breast biopsy: use and cost-effectiveness. Radiology. 1998; 208: 717-723.

  15. Liberman L, Ernberg L, Zakowski M. Palpable Breast Masses: is there a role for percutaneous Imaging-Guided Core Biopsy? AJR. 2000; 175: 779-787.

  16. Ciatto S, Houssami N, Ambrogetti D, Bianchi S, Bonardi R, Brancato B et al. Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies. Breast Cancer Res Treat. 2007; 101 (3): 291-297.

  17. Akıncı M, Bulut SP, Erözgen F, Gürbüzel M, Gülşen G, Kocakuşak A et al. Predictive value of fine needle aspiration biopsy of axillary lymph nodes in preoperative breast cancer staging. Ulus Cerrahi Derg. 2016; 32: 191-196.

  18. Mellado-Rodríguez M, Osa-Labrador AM. Cribado del cáncer de mama. Estado actual. Radiología. 2013; 55 (4): 305-314.

  19. Bruening W, Fontanarosa J, Tipton K, Treadwell JR, Launders J, Schoelles K. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Ann Intern Med. 2010; 152 (4): 238-246.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Mex Mastol. 2019;9